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Background: The Linear Array® (LA) genotyping test is one of the most used methodologies for Human papillomavirus
(HPV) genotyping, in that it is able to detect 37 HPV genotypes and co-infections in the same sample. However, the
assay is limited to a restricted number of HPV, and sequence variations in the detection region of the HPV probes could
give false negatives results. Recently, 454 Next-Generation sequencing (NGS) technology has been efficiently used also
for HPV genotyping; this methodology is based on massive sequencing of HPV fragments and is expected to be highly
specific and sensitive. In this work, we studied HPV prevalence in cervixes of women in Western Mexico by LA and
confirmed the genotypes found by NGS.
Methods: Two hundred thirty three cervical samples from women Without cervical lesions (WCL, n = 48), with Cervical
intraepithelial neoplasia grade 1 (CIN I, n = 98), or with Cervical cancer (CC, n = 87) were recruited, DNA was extracted,
and HPV positivity was determined by PCR amplification using PGMY09/11 primers. All HPV- positive samples were
genotyped individually by LA. Additionally, pools of amplicons from the PGMY-PCR products were sequenced
using 454 NGS technology. Results obtained by NGS were compared with those of LA for each group of samples.
Results: We identified 35 HPV genotypes, among which 30 were identified by both technologies; in addition, the
HPV genotypes 32, 44, 74, 102 and 114 were detected by NGS. These latter genotypes, to our knowledge, have not
been previously reported in Mexican population. Furthermore, we found that LA did not detect, in some diagnosis
groups, certain HPV genotypes included in the test, such as 6, 11, 16, 26, 35, 51, 58, 68, 73, and 89, which indicates
possible variations at the species level.
Conclusions: There are HPV genotypes in Mexican population that cannot be detected by LA, which is, at present, the
most complete commercial genotyping test. More studies are necessary to determine the impact of HPV-44, 74, 102
and 114 on the risk of developing CC. A greater number of samples must be analyzed by NGS for the most accurate
determination of Mexican HPV variants.
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Cervical cancer (CC) is the most frequent female cancer
worldwide, occupying fourth place among cancers in
women. In Mexico, the incidence of this pathology is high
(13,960 new cases each year), reaching second place for
cancers in women and causing 4769 deaths each year ac-
cording to Globocan 2012 [1]. Infection with HPV is the
principal etiological factor involved in the development of
CC [2]. To date, >202 HPV genotypes have been charac-
terized [3] and >40 have been reported to infect the female
genital tract [4, 5]. Globally, the HPV genotypes mainly as-
sociated with CC include HPV-16, 18, and 45 [6], but
these data vary depending on the geographic area. For ex-
ample, while HPV-35 and 45 are more prevalent in Africa,
the genotypes 52 and 58 are more frequently observed in
Asia, whereas 33 and 31 are more prevalent in Europe
and the USA [7–9]. Regarding Cervical intraepithelial
neoplasia grade 1 (CIN I), HPV-42 and 84 were reported
as more prevalent in Sweden [10], while in Chile, HPV-61
and 89 [11] are most prevalent, and in Asia, HPV-52 [12]
and in the USA (in rural American Indian women), HPV-
61 [13]. In Mexico, a recent study of our research group,
using genotyping by Linear Array, show that the HPV ge-
notypes most frequently found in cervical cancers were 16
(62.8 %), 18 (11.6 %), 45 (8.3 %), 52/58 (6.6 %), and 39
(5.8 %). Notably, a high percentage (58–64 %) of coinfec-
tions were found in CIN I—CIN III, suggesting that coin-
fections could contribute to regression or progression of
the cervical lesions [14].
All of these data suggest the need to develop detection
and prevention strategies consistent with the character-
istics of the geographic population.
There are few commercial methods available for HPV
genotyping [15], the majority of these are based on PCR
and reverse hybridization. However, this approach enter-
tains the drawback of only recognizing HPV genotypes
with sufficient dissimilarity for discrimination by probes
used in hybridization, allowing the detection of a restricted
number of HPV genotypes and not discriminating among
nucleotide variants. Next-Generation Sequencing (NGS),
or Massive parallel sequencing (MPS), has emerged as a
powerful tool for genotyping, possessing the advantage of
analyzing many samples at the same time. Recently, this
methodology has been used for the genotyping of HPV
[16–18]. In Mexico, there are few reports of HPV genotyp-
ing by means of LA and none, to our knowledge, employ-
ing NGS. In this work, we identified, by LA and NGS, the
HPV genotypes infecting the cervixes of woman from
Western Mexico.
Results
HPV genotyping by Linear Array test
From the 48 WCL samples, 12 (25 %) were positive for
HPV. Considering only HPV-positive samples, 58.3 %were reported as SI and 41.7 % as MI (Fig. 1). In the
CIN I group, 31 samples were found to be HPV-
negative (31.6 %) and 67 were HPV-positive (68.4 %).
Among the HPV-positive samples, 37 samples were SI
(55.2 %) and 30 were MI (44.8 %). In the CC sample
group, 100 % (n = 87) of the samples were infected with
HPV, 67.8 % with SI and 32.2 % with MI.
Calculating the frequency of HPV genotypes detected
by LA in the different groups analyzed (Table 1), we ob-
served that the most frequent HPV genotypes found in
WCL samples were 16, 51, and 84 (each found in the
25 % of HPV-infected women), followed by 56, 59, and
66 (16.7 % each), and last, HPV genotypes 6, 11, 31, 39,
52, 68, 81, and 89 (8.3 % frequency). Analysis in the CIN
I group showed that HPV-16 was the most frequent
genotype found in 20 of the 67 HPV-infected patients
(29.9 %), followed by genotypes 84 (17.9 %), 89 (13.4 %),
53 (10.4 %), 31 (9 %), and HPVs-39, 56, 58, 61, and 62
(7.5 %). HPV-66 was present in 6 % of the women of this
group, 16 additional HPV genotypes were found at fre-
quencies less than 4.5 %, as detailed in Table 1. On the
other hand, the CC group exhibited that HPV-16 was
also the most frequent genotype found (in 42 of 87
HPV-infected patients, 48.3 %), followed by 18 (18.4 %),
45 (10.3 %), 39 (9.2 %), 31, 52, and 71 (with 6.9 % fre-
quency each), 68 (5.7 %), and 19 additional HPV geno-
types with frequencies ranging between 4.6 and 1.1 %.
It is noteworthy that HPV-16 was the most frequent
genotype found in all analyzed groups. Interestingly,
HPV-52, 56, and 68 were found only in patients with
MI; and HPV-26, 69, 70, and 72, were detected only in
the CC group.
HPV genotyping by Next-Generation Sequencing
To corroborate the genotypes detected by LA and to
determine additional HPV not included in this test, NGS
was performed. All samples positive for HPV by LA, as
well as negative for LA but positive with PGMY09/11
primers, were included. Samples were pooled according
to diagnosis and SI or MI infection. Samples negative by
LA but positive with PGMY09/11 primers were desig-
nated as WCL (−) or CIN (−). As depicted in Fig. 2a,
after comparison of the sequences obtained with the hu-
man L1 papillomavirus database downloaded from PaVE,
75.4 % (58,481) of the reads were reported as unmapped
or not recognized as belonging to any reported HPV,
7.2 % (5549 reads) were tooshort (<100 pb), and finally,
17.4 % (13,482 reads) were found to be mapped with
HPV sequences. Median length of HPV reads was 450
nucleotides (nt), ranging between 404 and 468, while the
modal length of the reads was 460 nt.
Comparing the number of reads obtained by group, it
was observed that the greatest number of reads was ob-





































































Fig. 1 Schematic representation of samples genotyped by Linear Array (LA). This figure depicts the number of patients analyzed in each diagnosis
group (n), the percentage of Human papillomavirus (HPV) positivity, the percentage of HPV present as Single infection (SI) or Multiple infection (MI),
and the top five HPV genotypes present in each group. WCL =Without cervical lesion, CIN I = Cervical intraepithelial neoplasia grade I, CC = Cervical
cancer. (−) HPV negative with LA, (+) HPV positive with LA. HPV genotypes carcinogenic to humans are marked in red (International Agency for
Research on Cancer [IARC] classification)
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(Fig. 2b). However when we analyzed the proportion of
reads belonging to HPV by group, we observed that the
CC MI group produced the greatest number of reads,
followed by the CC SI, CIN SI, and CIN MI groups.
Groups CIN (−), WCL (−), and WCL (+) had low num-
bers of reads belonging to HPV in relation to the num-
bers of reads obtained in these groups. Of the total reads
that mapped to HPV, 228 sequences belonged to the
WCL (−) group, 121 to WCL (+), 118 to CIN I (−), 2685
to CIN I SI, 403 to CIN I MI, 4562 to CC SI, and 5365
to the CC MI group (Fig. 2b). Analyzing the total reads
obtained for each HPV genotype, the majority of reads
were from HPV-16 (4359 reads), followed by HPV-45
(3188 reads), HPV-68 (1244 reads), HPV-18 (1040
reads), and HPV-31 (617 reads) (Fig. 2c).
As depicted in Table 2, reads for each HPV were also
determine according to diagnosis group. In the WCL (−)
group (samples WCL negative for HPV by LA), we ob-
served the presence of HPV-26, 32, 44, and 51; of these
HPV, it is noteworthy that HPV-26 and 51 are included
in the LA test. In the WCL (+) group, nearly all geno-
types reported by LA were found, but additionally, HPV-
52, 81, and 89 were also found (despite that all of these
genotypes are included in the LA test). On the other
hand, the presence of HPV-6, 11, 31, 39, 56, and 68,
which were determined by LA in this group, was notconfirmed by NGS. Regarding the CIN I (−) group, we
were able to find, by means of NGS, 85 reads mapping
to HPV-16 and 33 reads that mapped to HPV-35, des-
pite that the test included both HPV genotypes. With re-
spect to the CIN I SI group, HPV-44 and 74 were
additionally found, genotypes that are not included in
LA. Similarly, in the CIN I MI group, additional HPV
genotypes that are not included in LA were detected by
NGS, such as 44, 102, and 114. In terms of the CC SI
group, HPV-11, 58, 68, 73, 81, 89, and 114 were identi-
fied by NGS, but not by LA. Among these, the LA test
possesses probes for nearly all HPV, but not for HPV-
102 nor for HPV-114. Finally, in the CC MI group,
HPV-58, 74, 102, and 114 were additionally detected
(Table 2). For comparison, all results obtained by LA in
each sample analyzed are contained in Additional file 1:
Table S1.
For a better overview of all NGS results, a summary
of HPV genotypes found according to diagnosis group
are depicted in Table 3, in which the HPV genotypes
found by LA and NGS are schematized in black; HPV
genotypes, in blue, found only by NGS despite their be-
ing included in the LA test; and in pink, genotypes
found only by NGS that are not included in LA. Those
HPV genotypes detected by LA and not by NGS were
also included (asterisk). Interestingly, by using NGS,
the following genotypes not included in the LA test
Table 1 Frequencies of each Human papillomavirus (HPV) genotype identified by Linear Array (LA) according to diagnosis group
The Table shows the number of patients (n) and the % of the frequency, in which each HPV genotype was found. WCL (Without cervical lesion), CIN I (Cervical
intraepithelial neoplasia grade I), CC (Cervical cancer), SI (Single infection), and MI (Multiple infection)
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Fig. 2 Next-Generation Sequencing (NGS) data. a Percentage of total reads obtained in the entire sequencing, grouped as unmapped, Human
papillomavirus (HPV)-mapped, or TooShort (eliminated). b Diagram of total reads obtained in each pooled study group (gray), including HPV
mapped reads (blue) obtained in each group utilizing the HPV reference sequence from the Papillomavirus Episteme (PaVE) database. c Total
reads mapped with each HPV genotype independent of the diagnosis group
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analyze the presence of each HPV by diagnosis group,
we may observe that HPV-16 was detected in six of the
seven analyzed groups, HPV-59 was detected in five
groups, HPV-31 and 66 in four groups, and the remain-
der of HPV genotypes was found in three or two
groups. Genotypes identified in only one group com-
prised HPV-11 in CC SI, 32 in WCL (−), 56 in CIN I
MI, 67 in CIN I SI, 69 in CC MI, and 70 in CC MI, as
can be observed in Table 3.
Finally, consensus sequences (contigs) of each HPV
genotype found exclusively among the Mexican samples
analyzed were aligned and a phylogenetic tree was con-
structed (Fig. 3). As expected, HPV contigs were grouped
according to the present classification. Exception includedHPV-54, found more closely related with HPV-6, 11, 44,
and 74. To supplement these data, next to each genotype
is displayed the diagnosis group in which the sequences
were found (WCL, CIN I, or CC). To contrast these re-
sults, we noted that HPV-11, 18, 68, 69, and 70 were only
found in CC, whereas HPV-32 and 51 were only found in
the WCL group. On the other hand, HPV-31, 33, 35, 39,
45, 54, 58, 62, 73, 74, 102, and 114 were present in CIN I
and CC, whereas HPV-44 and 84 were found in the WCL
and CIN I groups.
Discussion
Cervical cancer remains a public health problem in
Mexico, despite the prevention and vaccination campaigns
implemented by the government. Vaccination is
Table 2 Number of reads obtained for each Human papillomavirus (HPV) genotype according to study group
HPV genotypes in blue are those not recognized by Linear Array (LA). HPV genotypes in black were found by Next-Generation Sequencing (NGS) and LA. HPV
genotypes with asterisk are those included in the LA test, but were only recognized by NGS. WCL (Without cervical lesion), CIN I (Cervical intraepithelial neoplasia
grade I), CC (Cervical cancer), (−) HPV-negative with LA, (+) HPV-positive with LA, SI (Single infection), and MI (Multiple infection)
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in the near future, and this probably would impact dif-
ferentially, depending on the geographic region, be-
cause it has been shown that HPV genotype frequency
varies among the different countries [19–22]. Thus,
there are local efforts to develop population-specific di-
rected HPV vaccines; however, to develop a vaccine
specific for a geographic population, it is essential to
first know the HPV genotypes circulating in the popula-
tion. In this study, we detected the HPV genotypes that
are infecting women from Western Mexico, not only by
LA, which is the commercial test with the major num-
ber of genotypes included, but also by NGS, to identify
the widest possible genotypes. Results obtained by LA
were very similar to those previously reported and dis-
cussed by our IMSS Research Network on HPV [14];
however, the use of 454 NGS allowed us to identify pre-
viously not reported HPV genotypes in Mexican popu-
lation. NGS is a technology that has been efficiently
used for HPV genotyping; this methodology is based onMassive Sequencing (MS) of HPV fragments from a
great number of genotypes, even when these are in low
in copy number [16, 18].
Using 454 NGS, we could detect genotypes not in-
cluded in LA: 32, 44, 74, 102, and 114 (1, 79, 2, 2, and
30 reads, respectively). We found HPV-32 only in the
WCL group; this genotype has been associated with oral
focal epithelial hyperplasia [23, 24] and oral papilloma-
tous lesions from patients with Human immunodefi-
ciency virus (HIV) infection [25]. In another study, in a
search for uncommon and rare HPV genotypes in cer-
vical carcinomas, HPV-32 was not found [26]. On the
other hand, characterization of the properties of HPV-32
E6 and E7 oncoproteins have provided evidences of the
benign nature of this genotype [27].
With respect to HPV-44, we detected this genotype in
WCL or CIN I samples, but not in CC. This HPV was
isolated for the first time from a vulvar condyloma, and
was found in five cases of 439 normal squamous epithe-
lium samples and in three cases of 112 CIN I samples,
Table 3 Summary of all Human papillomavirus (HPV) genotypes
determined by Next-Generation Sequencing (NGS) in each study
group
Pink checkmarks represent HPV genotypes found only by NGS that are not
included in Linear Array (LA); blue checkmarks represent HPV genotypes only
detected by NGS, despite their being included in LA; black checkmarks are HPV
genotypes found both by LA and by NGS. HPV genotypes detected by LA but
not by NGS are marked with an asterisk. Boxes in pink represent genotypes
reported as “carcinogenic to humans”, in gray as “probably carcinogenic”, and in
purple as “possibly carcinogenic” (International Agency for Research on Cancer
[IARC] classification)
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However, this genotype has been found in patients with
invasive cervical cancer in Africa with a frequency of
1.8 % of co-infection with other HPV genotypes [29].
Additionally, it has been detected in patients with HIV
with a frequency of 12.5 % in South Africa, Ghana, and
Nigeria [29], and has been also reported in anogenital
carcinoma [30]. In other studies, the prevalence of HPV-
44 has been reported as ranging from 0.4–5 % [31–34].
HPV-74 has been found in low-grade vaginal intrae-
pithelial neoplasia in immunosuppressed women and
has been related phylogenetically with HPV-6, 11, 44,
and 55 [35, 36]. We found this genotype only in some
patients of the CIN I SI and CC MI groups. The number
of reads obtained for HPV-74 was very low, suggesting a
low prevalence. In this regard, low prevalence of HPV-
74 has been detected by LiPA assay in genital warts in a
German population [34]; additionally, HPV-74 has also
been reported as present in male populations from
Brazil, Mexico, and the USA (by direct sequencing of
products from nested PCR of the L1 region) [37].
HPV-102 has been also found in this study only by
NGS; we detected it in CIN I and CC, both in MI
(Table 3). Despite that we found only one read in each
group, we consider this genotype as present, because the
sequences obtained are sufficient (337 and 411 bp) and
identity was 99 and 100 %, respectively. Additionally,
phylogenetic tree analysis places this genotype in alpha
species 3 (Fig. 3), as also reported [36]. It is important to
mention that we used all HPV reference sequences from
the L1 alpha species for mapping. It has been reported
that “simultaneous mapping” significantly decreases the
read numbers obtained [38], but we consider that it is
better because more solid data are obtained. In agree-
ment with our findings, this genotype has been detected
in cervicovaginal cells from Hispanic females [39].
Other additional genotype detected in our study, only
by NGS, was HPV-114; this is a recently characterized
papillomavirus isolated from a low-grade cervical lesion,
and it has been found in low-grade samples with 1.7 %
prevalence [40]. We found this genotype in CIN I MI and
CC, both SI and MI; its presence in CC suggest a possible
oncogenic risk that needs to be evaluated individually in
more samples. HPV-114 has also been detected by NGS
in a Swedish cervical sample [17], and has been found in
one case of Vulvar intraepithelial neoplasia (VIN) [41].
To complement and summarize our results, it was in
our interest to performed a phylogenetic tree exclusively
with sequences obtained by NGS from Mexican samples
(Fig. 3); reconstruction shows a very similar pattern ac-
cording to the classification of de Villiers [36] despite
using approximately 450 bp of the L1 region amplified
by the PGMY09/11 set of primers. Bernard et al. in
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Fig. 3 Phylogenetic tree built with the total Human papillomavirus
(HPV) consensus sequences identified in Mexican cervical samples
analyzed. Analysis was performed by MEGA6 software displayed as
Topology. The diagnosis group in which each HPV genotype was
detected is also depicted. Blue circle: WCL (Without cervical lesion),
Orange circle: CIN I (Cervical intraepithelial neoplasia grade I), and
Red circle: CC (Cervical cancer)
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sons [42].
It is accepted that in order to recognize a new Papilloma-
virus (PV) type, its complete genome must be cloned and
its L1 gene sequence must be different in 10 % from the
closest type known; differences between 2 and 10 % repre-
sent a subtype, and differences <2 %, a variant [43]. By ana-
lysis with the GS Reference Mapper, a variety of putative
high-confidence nucleotide differences were determined,
principally in HPV genotypes 31, 39, 45, 62, 66, 68, and 69.
These nucleotide differences were found in two or more
diagnosis groups (taking into account differences detected
in at least 50 reads). Therefore, we continue to not discard
the existence of HPV variants present in Mexico.Regarding the classification of carcinogenicity for
humans used by the International Agency for Research on
Cancer (IARC) [44], there are some HPV genotypes that
are classified as “probably” or “possibly” carcinogenic or
not classifiable. Among those, we found HPVs-11, 68, 70,
and 69 only in CC samples. In contrast, HPVs-32, 44, 51,
and 84 were observed in only the WCL and/or in the CIN
I group. With regard to HPV genotypes not previously re-
ported in Mexican population, HPV-74, 102, and 114 were
detected in the CIN I and CC groups.
One limitation of this study was that groups of samples
(according to the diagnosis), but not individually samples,
were sequenced. Additionally, the HPV-genotypes de-
tected were limited to the amplicons obtained by using
the PGMY09/11 set of primers.
We continue to recruit and analyze additional cervical
samples in order to corroborate and report these observa-
tions. Genotyping of HPV by NGS will permit the detection
of more possible HPV variants, whose sequences could in-
crease or diminish HPV recognition by the immune system
or modify the oncogenic potential of HPV proteins [45].
We continue to need more studies with methodologies
such as NGS to determine the HPV genotypes and vari-
ants circulating in Mexican population and at the differ-
ent stages during CC progression.
Conclusions
To our knowledge, this is the first time that data has
been reported on HPV genotypes circulating in Mexico
by using Massive parallel sequencing (MPS). Our data
provide helpful information because we were able to find
not previously detected HPV genotypes in Mexican
population. The methodological strategy employing the
PGMY09/11 primers appears to be a very good system.
Methods
Sample collection
Approximately 250 cervical samples were obtained from
the Centro Médico Nacional de Occidente (CMNO,
IMSS) located in Guadalajara, Jalisco, Western Mexico.
The women whose samples were taken attended a med-
ical examination due to a cervical ailment. Diagnosis
was first performed only by colposcopy observation
(visual inspection using acetic acid and Lugol’s iodine
solution); when cervical lesions/cancer were (was) ob-
served, a biopsy was taken for diagnosis confirmation
by histopathology. From the 250 samples obtained, 17
samples were excluded (those samples without suffi-
cient quantity and quality of DNA), therefore, 233 sam-
ples were included in this study: 48 WCL; 98 CIN I,
and 87 CC. Ages of the participating women ranged from
25–65 years. Samples were obtained by inserting a cyto-
brush into the endocervical canal, rotating it for 3–5 full
turns, and placing it into ThinPrep PreservCyt® transport
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Marlborough, MA, USA).
HPV screening and Linear Array® HPV genotyping test
Total DNA was extracted and purified from each
cervical sample using the AmpliLute Liquid Media Ex-
traction Amplicor Kit (Cat. no. 03750540 190; Roche
Molecular Systems, Inc., Branchburg, NJ, USA.). A first
screening for HPV positivity was performed by conven-
tional single-round PCR utilizing PGMY09/11 primers,
which amplified a 450-bp fragment of L1 [46]. HPV-
positive samples were genotyped utilizing the Linear
Array® HPV Genotyping test (Cat. no. 04391853 190;
Roche Molecular Diagnostics, Pleasanton, CA, USA),
which is capable of detecting simultaneously up to 37
HPV genotypes in a sample [47]. This assay includes, as
control, β-globin amplification in the same PCR reac-
tion. According to the results obtained by LA, samples
were subdivided into HPV-negative (−) or HPV-positive
(+), and into Single- or Multiple infection (SI or MI,
respectively).
HPV sequencing by 454 NGS
All HPV-positive samples identified by conventional
PCR utilizing PGMY09/11 primers were included for
MS. Amplicons for the NGS Library were generated by
taking approximately 500–1000 ng of DNA from each
sample and amplification by conventional PCR employ-
ing the following specifically designed primers: Forward
5′-[Universal Multiplicom tail A: AAGACTCGGCAGC
ATCTCCA] – [individually PGMY11 primer]-3′, and
Reverse 5′-[Universal Multiplicom tail B: GCGATCGTC
ACTGTTCTCCA] – [individually PGMY09 primer]-3′.
The PGMY sequences used were those reported in
Table 2 in Gravitt et al. [46]. Universal Multiplicom tails
A and B were the same used in Cat. no. MR-0020.024,
Multiplicom NV CFTR; Molecular Diagnostics, Niel,
Belgium. PCR conditions included 1 cycle at 94 °C for
3 min, followed by 40 cycles at 94 °C for 45 s, 48 °C for
30 s, and 72 °C for 60 s, and a final cycle at 72 °C for
10 min. The PCR products (~450 pb) were electropho-
resed in 1.5 % agarose gels, and cut and purified with
the Wizard® SV Gel and PCR Clean-Up System (Cat. no.
A9282; Promega, Madison, WI, USA).
Purified amplicons generated from each sample were
quantified with the Qubit® dsDNA HS fluorometry assay
Kit (Cat. no. Q32851; Life Technologies™, Eugene, OR,
USA) to carry out 5-ng amplicon pools per sample.
Amplicon pools were generated for the NGS Library, tak-
ing into account diagnosis, HPV negativity or positivity
observed by LA, and the SI- or MI-HPV infection de-
tected in a same sample. The following groups were
generated: WCL (−), samples WCL-negative for HPV
by LA; WCL (+), samples WCL-positive for HPV byLA; CIN I (−), CIN I samples negative for HPV by LA;
CIN I SI, CIN I samples with single HPV infection;
CIN I MI, CIN I samples infected with 2 or more
HPVs, and CC SI and CC MI.
A second PCR reaction was performed to add the
Multiplex identifiers (MID) barcodes, the key sequence
(TCAG), and A or B sequencing adapters by using Multi-
plicom 454 MID Kits (Cat. no. ML-0008.192 and ML-
0016.192, Multiplicom NV CFTR; Molecular Diagnostics)
according to the manufacturer’s instructions. Amplicons
where then purified with Agentcourt® AMPure® XP beads
(Cat. no. A63881; Beckman Coulter Genomics, Danvers,
MA, USA) and evaluated with the 2100 Bioanalyzer
system (Cat. no. G2940CA; Agilent Technologies, Santa
Clara, CA, USA).
The emulsion Polymerase chain reaction (emPCR) was
performed with the GS Junior Titanium emPCR kit Lib
A (Cat. no. 05996520001; Roche Diagnostics), and
amplicons were sequenced in a GS Junior Sequencer
utilizing the GS Junior Titanium Sequencing Kit (Cat.
no. 05996554001) and the GS Junior Titanium PicoTi-
terPlate Kit (Cat. no. 0599661900), following the manu-
facturer’s instruction. All kits were supplied by Roche
Diagnostics, Basel, Switzerland.Data analysis
Quality control for sequencing data was performed,
sequences with a Phred quality score of <20 were elimi-
nated, and primer sequences were trimmed. The Roche
GS Reference Mapper (ver. 2.9) was used to identify
HPV genotypes by comparing fragment sequences with
the L1 region of alpha and beta papillomavirus reference
sequences, downloaded from Papillomavirus Episteme
(PaVE) [48]. Specific reads for each diagnosis group were
identified in accordance with their associated MID
barcode.Analysis of phylogenic ancestry
Construction of a phylogenetic tree with consensus se-
quences of each HPV was performed. First, all consensus
sequences were aligned utilizing MEGA6 software
(employing the ClustalW ver. 1.6 algorithm), followed by
the construction of the phylogenetic tree with the max-
imum likelihood method. Traditional tree-branch style
was chosen and the Topology display was selected.Ethical approval
This study was approved by the Ethics and Research
Committees of the Instituto Mexicano del Seguro Social
(IMSS), with registration number R-2014-785-036. All
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Flores-Miramontes et al. Virology Journal  (2015) 12:161 Page 10 of 11Additional file
Additional file 1: Table S1. Human papillomavirus (HPV) genotypes
identified by Linear Array (LA). The Table shows the HPV genotypes
found in each sample analyzed and grouped according to diagnosis.
WCL (Without cervical lesion), CIN I (Cervical intraepithelial neoplasia
grade I), CC (Cervical cancer), SI (Single infection), and MI (Multiple
infection). (PDF 20 kb)
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